<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14257">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921282</url>
  </required_header>
  <id_info>
    <org_study_id>134-2015</org_study_id>
    <nct_id>NCT02921282</nct_id>
  </id_info>
  <brief_title>Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms</brief_title>
  <official_title>Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, potential associations between several genetic polymorphisms and nicotine
      dependence will be examined. The relative reinforcing efficacy of cigarettes using the
      forced-choice procedure will be assessed. In addition, reactivity to smoking cues using a
      reliable procedure will be conducted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is known that cannabinoid and dopamine receptors can be important modulators of response
      to nicotine and its associated cues. In this study participants will be genotyped to
      determine whether there is a relationship between CB1 or D3 genes and the reinforcing
      properties of nicotine or the subjective effects of nicotine-associated cues. In one
      session, participants will chose between two different cigarettes, each with different
      properties. In another session, physiological responses and craving will be measured when
      presented with cues that remind participants of nicotine. At some point during the study,
      blood will be collected for genotyping and this will processed to study whether CB1 or D3
      genotype influences these responses to nicotine or cues.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of puffs on a cigarette</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Craving in response to nicotine cues</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiological measures in response to cues</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cigarette Smoking Behavior</condition>
  <arm_group>
    <arm_group_label>Genotype dopamine</arm_group_label>
    <description>Genotyping will be conducted at the conclusion of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotype cannabinoids</arm_group_label>
    <description>Genotyping will be conducted at the conclusion of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genotype dopamine</intervention_name>
    <description>Laboratory investigations of nicotine reinforcement</description>
    <arm_group_label>Genotype dopamine</arm_group_label>
    <arm_group_label>Genotype cannabinoids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genotype cannabinoids</intervention_name>
    <description>Laboratory investigations of nicotine reinforcement</description>
    <arm_group_label>Genotype dopamine</arm_group_label>
    <arm_group_label>Genotype cannabinoids</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Otherwise healthy smokers will be recruited
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19-64 year old males and females

          2. smoking at least 10 cigarettes per day for at least 1 year

          3. urinary cotinine level ≥ 100 ng/ml (NicAlert® reading ≥ 3)

          4. medically and psychologically healthy as determined by screening criteria

        Exclusion Criteria:

          1. definite plan to reduce or quit tobacco use in the next 30 days

          2. treatment for tobacco dependence in the past 3 months

          3. use of nicotine replacement products, bupropion, or varenicline in the past 3 months

          4. consumption of more than 15 alcoholic drinks per week during the past month

          5. use of any illicit drug more than twice per week during the past month

          6. current use of any medication that would interfere with the protocol in the opinion
             of PI

          7. under the influence of a drug or alcohol at any session

          8. pregnant, nursing, or become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Le Foll, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Di Ciano, PhD</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>34002</phone_ext>
    <email>patricia.diciano@camh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernard Le Foll, MD PhD</last_name>
    <phone>416 535-8501</phone>
    <phone_ext>34772</phone_ext>
    <email>bernard.lefoll@camh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 1S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia DiCiano, PhD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>34002</phone_ext>
      <email>Patricia.DiCiano@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Chidera Chukwueke, BSc</last_name>
      <phone>416-535-8501</phone>
      <email>chidera.chukwueke@camh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Bernard Le Foll, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>October 3, 2016</lastchanged_date>
  <firstreceived_date>September 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Bernard Le Foll</investigator_full_name>
    <investigator_title>Scientist</investigator_title>
  </responsible_party>
  <keyword>genes</keyword>
  <keyword>cues</keyword>
  <keyword>reward</keyword>
  <keyword>smoking</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with collaborators at NIDA-IRP</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
